APA (7th ed.) Citation

Y, L., Y, Z., C, L., Z, F., S, L., G, W., & G, M. (2026). Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models. Frontiers in public health, 14, 1841510. https://doi.org/10.3389/fpubh.2026.1841510

Chicago Style (17th ed.) Citation

Y, Li, Zou Y, Liang C, Feng Z, Lu S, Wang G, and Meng G. "Pharmacoeconomic Evaluation of First-line Tislelizumab for Extensive-stage Small Cell Lung Cancer Using a Comparative Validation of Traditional Survival and Machine Learning Models." Frontiers in Public Health 14 (2026): 1841510. https://doi.org/10.3389/fpubh.2026.1841510.

MLA (9th ed.) Citation

Y, Li, et al. "Pharmacoeconomic Evaluation of First-line Tislelizumab for Extensive-stage Small Cell Lung Cancer Using a Comparative Validation of Traditional Survival and Machine Learning Models." Frontiers in Public Health, vol. 14, 2026, p. 1841510, https://doi.org/10.3389/fpubh.2026.1841510.